跳至主要内容
临床试验/ACTRN12612000853842
ACTRN12612000853842已完成未知

A Prospective Randomized Controlled Trial Assessing the Efficacy of Withdrawing Alpha-blocker Following Initial Combination Therapy with 5-Alpha Reductase Inhibitor for Benign Prostatic Hyperplasia

niversiti Kebangsaan Malaysia Medical Centre0 个研究点目标入组 102 人开始时间: 2012年8月14日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
102

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
40 Years 至 80 Years(—)
性别
Male

入选标准

  • patients with moderate or severe BPH based on IPSS score who were newly diagnosed and started on combination therapy or who were previously diagnosed and were already on combination therapy for a duration of not more than one year. All patients on combination therapy had a prostate size of more than 40g as assessed by digital rectal examination

排除标准

  • All patients had a baseline PSA taken routinely and patients with a value higher than 4ng/ml underwent biopsy to screen for possible malignancy. Patients with PSA value less than 1.5ng/ml, prostate cancer and patients with recurrent urinary tract infections were excluded from our study.

研究者

发起方
niversiti Kebangsaan Malaysia Medical Centre

相似试验